13th Croatian Congress on Atherosclerosis with International Participation

hda logo hda logo
hazu logo

UNDER THE AUSPICES OF
CROATIAN ACADEMY OF SCIENCES AND ARTS

laptop

PROGRAM

Congress day from 15:00 to 19:00h

1. Željko Reiner, Velimir Neidhardt, Vida Demarin

13th Croatian Congress with International Participation - Welcome lecture

13. Hrvatski kongres s međunarodnim sudjelovanjem - Pozdravno predavanje

2. Češka Richard

FH: The Experience from ScreenPro FH project

Porodična hiperkolesterolemija: iskustvo projekta ScreenPro FH

3. Maciej Banach

Drucebo or nocebo effect? How to diagnose, how to manage? ILEP Recommendations 2021

Učinak druceba ili noceba? Kako postaviti dijagnozu i kako liječiti? Preporuke ILEP-a za 2021. godinu.

4. Lale Tokgözoğlu

New era in lipid lowering therapies

Novo razdoblje u liječenju sniženja lipida

5. Michal Vrablik

Genetics of Cardiovascular Disease: How Far Are We from Personalized CVD Risk Prediction and Management?

Genetika kardiovaskularnih bolesti: Koliko smo daleko od personaliziranog predviđanja i liječenja rizika za kardiovaskularne bolesti?

6. Kausik Ray

Implementing ESC guidelines From Da Vinci to Heymans

Implemetiranje smjernica Europskog kardiološkog društva od Da Vinci do Heymans

7. Frederick Raal

Familial hypercholesterolaemia: a step towards achieving optimal treatment targets with newer therapies - sponsored by Novartis

Porodična hiperkolesterolemija: korak prema postizanju optimalnih ciljeva liječenja s novim lijekovima - sponzor Novartis

8. Raul Santos

Heterogeneity in cardiovascular risk in Familial Hypercholesterolemia: an example of precision medicine

Heterogenost kardiovaskularnog rizika u porodičnoj hiperkolesterolemiji: primjer precizne medicine

9. Alberto Zambon

Omega n-3 fatty acids and CV benefits: much more than lipids

Omega n-3 masne kiseline i kardiovaskularna korist: mnogo više nego djelovanje na lipide

10. Ezhov Marat

Lipoprotein(a): what is new?

Lipoprotein(a): što ima novoga?

11. Christie Mitchell Ballantyne

Treatment of lipids: update on new therapies and new targets in development

Liječenje lipida: nove mogućnosti I novi ciljevi

12. Dan Gaita

Strategies for improving LDL-cholesterol goal attainment - the vital role of PCSK9 inhibitors!

Strategija za poboljšanje postizanja ciljnih vrijednosti LDL-kolesterola- ključna uloga inhibitora PCSK9!

13. Zlatko Fras

Universal screening for FH - the Slovenian experience

Probir populacije za porodičnu hiperkolesterolemiju – slovensko iskustvo

14. RASPRAVA UŽIVO - LIVE DISCUSSION 19:00 - 20:00h

chat discussion with lecturers

chat rasprava s predavačima

Congress day from 09:00 to 13:00h

1. Bojan Jelaković

Cardiovascular risk factors in general population of Croatia – EHUH – 2 study

Učestalost kardiovasklarnih čimbenika rizika u općoj populaciji Hrvatske- EHUH -2 studija

2. Nada Božina

Pharmacogenomic and individualisation of treatment with hypolipemics

Farmakogenomika i individualizacija terapije hipolipemicima

3. Vida Demarin

Lifestyle factors in prevention of cognitive decline

Čimbenici načina života u prevenciji kognitivnih poremećaja

4. Fran Borovečki

Hyperlipidemia as a basis for neurodegerative processes

Hiperlipidemija kao osnova neurodegenerativnih procesa

5. Luka Zaputović

Phenotype profiles of patients and personalized treatment of heart failure

Fenotipski profili bolesnika i personalizirano liječenje zatajivanja srca

6. Iveta Merćep

Intolerance to statins

Intolerancija na statine

7. Diana Muačević Katanec

Personalized approach to treatment of dislipidemias

Personalizirani pristup liječenju dislipidemija

8. Jadranka Sertić

Epigenomics and atherosclerosis

Epigenomika i ateroskleroza

9. Ivan Pećin

PCSK9i are changing treatment patterns for high risk and very high risk patients

Inhibitori PCSK9 mijenjaju način liječenja bolesnika sa velikim i vrlo velikim kardiovaskularnim rizikom

10. Željko Reiner

New 2021 on ESC Guidelines for prevention cardiovascular disease prevention in clinical practice

Nove smjernice Europskog kardiološkog društva za prevenciju kardiovaskularnih bolesti u kliničkoj praksi 2021. godine

11. Davor Miličić

Cardiovascular risk 2021

Kardiovaskularni rizik 2021.

12. RASPRAVA UŽIVO - LIVE DISCUSSION 13:00 -14:00h

chat discussion with lecturers

chat rasprava s predavačima

SPONSORS

Without their help and support it would not have been possible to organize the congress therefore we list them with gratitude!